{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:08:52Z","timestamp":1793815732845,"version":"4.6.1"},"reference-count":92,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Based on the hypothesis that neovascularization was required for tumor growth, the search for angiogenesis inhibitors attracted considerable attention, leading to the development of the monoclonal antibody bevacizumab against vascular endothelial growth factor (VEGF) which is currently standard treatment in several types of cancer. However, and despite encouraging preclinical data, clinical trials frequently failed to translate into benefits for patients due to limited efficacy, resistance and toxicity. Resistance mechanisms include triggering of alternative proangiogenic pathways, non-angiogenic vascularization, and the unforeseen heterogeneity of tumor endothelial cells. Early efforts to disrupt key interactions between extracellular matrix and endothelial cells via integrin or metalloproteinase inhibitors also had modest clinical outcomes, mainly due to poor selectivity and compensatory mechanisms. Similarly, the promise of endogenous angiogenesis inhibitors like endostatin and angiostatin did not led to durable clinical responses. Recent studies have shown that VEGF contributes to immune suppression, and therefore anti-VEGF therapy can not only normalize vasculature, improving immune infiltration, but also help to reshape tumor microenvironment. This has led to successful combinations of antiangiogenic agents and immune checkpoint inhibitors, now approved in several indications, including renal cell and hepatocellular carcinomas. Based on these results, bispecific antibodies targeting simultaneously VEGF and PD-(L)1 are emerging as promising therapeutic agents, with several worldwide phase 3 trials ongoing. Globally, around twenty bispecifics and trispecifics are in clinical development. In this review, we recapitulate previous successes and failures of anti-angiogenic strategies, and explore the potential of VEGF x PD-(L)1 antibodies as a new paradigm in cancer treatment.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1736806","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T06:47:44Z","timestamp":1769150864000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Anti-angiogenic therapies in cancer: from endogenous inhibitors to bispecific VEGF x PD-(L)1 antibodies"],"prefix":"10.3389","volume":"17","author":[{"given":"Luis","family":"\u00c1lvarez-Vallina","sequence":"first","affiliation":[{"name":"CNIO-HMRIB Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid-Hospital del Mar Research Institute Barcelona (HMRIB)","place":["Madrid\/ Barcelona, Spain"]},{"name":"Banc de Sang i Teixits","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Sanz","sequence":"additional","affiliation":[{"name":"Molecular Immunology Unit, Biomedical Research Institute Hospital Universitario Puerta de Hierro-Segovia de Arana Majadahonda (IDIPHISA)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00671-z","article-title":"Targeting angiogenesis in oncology, ophthalmology and beyond","volume":"22","author":"Cao","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00780-7","article-title":"Milestones in tumor vascularization and its therapeutic targeting","volume":"5","author":"De Palma","year":"2024","journal-title":"Nat Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahjo.2022.100144","article-title":"Vascular endothelial growth factor-tyrosine kinase inhibitors: Novel mechanisms, predictors of hypertension and management strategies","volume":"17","author":"Gomez","year":"2022","journal-title":"Am Heart J Plus"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00867-X","article-title":"Angiogenesis inhibition in metastatic colorectal cancer continuum of care","volume":"402","author":"Martinelli","year":"2023","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2297450","article-title":"Antibodies to watch in 2024","volume":"16","author":"Crescioli","year":"2024","journal-title":"mAbs"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101540","article-title":"Suvemcitug as second-line treatment of advanced or metastatic solid tumors and with FOLFIRI for pretreated metastatic colorectal cancer: phase Ia\/Ib open label, dose-escalation trials","volume":"8","author":"Mao","year":"2023","journal-title":"ESMO Open"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA5516","article-title":"A phase III randomized, double-blinded, placebo-controlled study of suvemcitug combined with chemotherapy for platinum-resistant ovarian cancer (SCORES)","volume":"42","author":"Yuan","year":"2024","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00772-9","article-title":"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study","volume":"402","author":"Dasari","year":"2023","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-023-09876-7","article-title":"Pathological angiogenesis: mechanisms and therapeutic strategies","volume":"26","author":"Dudley","year":"2023","journal-title":"Angiogenesis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01288-1","article-title":"Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments","volume":"20","author":"Wei","year":"2021","journal-title":"Mol Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4197","article-title":"Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases","volume":"22","author":"Frentzas","year":"2016","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-023-00591-5","article-title":"Understanding tumour endothelial cell heterogeneity and function from single-cell omics","volume":"23","author":"Zeng","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1126\/science.289.5482.1197","article-title":"Genes expressed in human tumor endothelium","volume":"289","author":"St Croix","year":"2000","journal-title":"Science"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.12.001","article-title":"An integrated gene expression landscape profiling approach to identify lung tumor endothelial cell heterogeneity and angiogenic candidates","volume":"37","author":"Goveia","year":"2020","journal-title":"Cancer Cell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33052-y","article-title":"Single cell atlas identifies lipid-processing and immunomodulatory endothelial cells in healthy and Malignant breast","volume":"13","author":"Geldhof","year":"2022","journal-title":"Nat Commun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109253","article-title":"Tumor vessel co-option probed by single-cell analysis","volume":"35","author":"Teuwen","year":"2021","journal-title":"Cell Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/s1471-4914(03)00070-4","article-title":"The extracellular matrix: a new turn-of-the-screw for anti-angiogenic strategies","volume":"9","author":"Sanz","year":"2003","journal-title":"Trends Mol Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adg3840","article-title":"The extracellular matrix as hallmark of cancer and metastasis: from biomechanics to therapeutic targets","volume":"16","author":"Sleeboom","year":"2024","journal-title":"Sci Transl Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.12.001","article-title":"Integrin \u03b1v\u03b26-TGF\u03b2-SOX4 pathway drives immune evasion in triple-negative breast cancer","volume":"39","author":"Bagati","year":"2021","journal-title":"Cancer Cell"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106694","article-title":"The challenges and opportunities of \u03b1v\u03b23-based therapeutics in cancer: From bench to clinical trials","volume":"189","author":"Gu","year":"2023","journal-title":"Pharmacol Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11070978","article-title":"Are integrins still practicable targets for anti-cancer therapy","volume":"11","author":"Alday-Parejo","year":"2019","journal-title":"Cancers"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nov018","article-title":"End of the road: confounding results of the CORE trial terminate the arduous journey of cilengitide for glioblastoma","volume":"17","author":"Mason","year":"2015","journal-title":"Neuro Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1941","article-title":"Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors","volume":"15","author":"Reynolds","year":"2009","journal-title":"Nat Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/advs.201902746","article-title":"MT1-MMP-activated liposomes to improve tumor blood perfusion and drug delivery for enhanced pancreatic cancer therapy","volume":"7","author":"Wei","year":"2020","journal-title":"Adv Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00284-4","article-title":"Emerging therapeutic opportunities for integrin inhibitors","volume":"21","author":"Slack","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10662","article-title":"Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin","volume":"102","author":"Borsi","year":"2002","journal-title":"Int J Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA9501","article-title":"Phase 3 study (PIVOTAL) of neoadjuvant intralesional daromun vs. immediate surgery in fully resectable melanoma with regional skin and\/or nodal metastases","volume":"42","author":"Hauschild","year":"2024","journal-title":". J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-001-0235-5","article-title":"Generation and characterization of recombinant human antibodies specific for native laminin epitopes: potential application in cancer therapy","volume":"50","author":"Sanz","year":"2001","journal-title":"Cancer Immunol Immunother"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/cdg150","article-title":"A novel cell binding site in the coiled-coil domain of laminin involved in capillary morphogenesis","volume":"22","author":"Sanz","year":"2003","journal-title":"EMBO J"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18794-x","article-title":"Concepts of extracellular matrix remodelling in tumour progression and metastasis","volume":"11","author":"Winkler","year":"2020","journal-title":"Nat Commun"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/35036374","article-title":"Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis","volume":"2","author":"Bergers","year":"2000","journal-title":"Nat Cell Biol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.8.3884","article-title":"Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model","volume":"97","author":"Fang","year":"2000","journal-title":"Proc Nat Acad Sci USA"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0646","article-title":"Matrix metalloproteinase inhibitors in cancer therapy: turning past failures into future successes","volume":"17","author":"Winer","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4390","article-title":"Is there new hope for therapeutic matrix metalloproteinase inhibition","volume":"13","author":"Vandenbroucke","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003580","article-title":"Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival","volume":"9","author":"Shah","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2023.2284935","article-title":"An updated patent review of matrix metalloproteinase (MMP) inhibitors (2021-present)","volume":"33","author":"Banerjee","year":"2023","journal-title":"Expert Opin Ther Pat"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-2427","article-title":"Endogenous inhibitors of angiogenesis","volume":"65","author":"Nyberg","year":"2005","journal-title":"Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90200-3","article-title":"Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma","volume":"79","author":"O\u2019Reilly","year":"1994","journal-title":"Cell"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(00)81848-6","article-title":"Endostatin: an endogenous inhibitor of angiogenesis and tumor growth","volume":"88","author":"O\u2019Reilly","year":"1997","journal-title":"Cell"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1006\/mthe.2002.0573","article-title":"Unfulfilled promise of endostatin in a gene therapy xenotransplant model of human acute lymphocytic leukemia","volume":"5","author":"Eisterer","year":"2002","journal-title":"Mol Ther"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.061","article-title":"Phase I study of recombinant human endostatin in patients with advanced solid tumors","volume":"20","author":"Herbst","year":"2002","journal-title":"J Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.12.120","article-title":"Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors","volume":"21","author":"Thomas","year":"2003","journal-title":"J Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-023-02245-w","article-title":"Recombinant human endostatin as a potential anti-angiogenic agent: therapeutic perspective and current status","volume":"41","author":"Anakha","year":"2023","journal-title":"Med Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.15171\/apb.2017.004","article-title":"The challenges of recombinant endostatin in clinical application: focus on the different expression systems and molecular bioengineering","volume":"7","author":"Mohajeri","year":"2017","journal-title":"Adv Pharm Bull"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21851","article-title":"Enhanced antiangiogenic therapy with antibody-collagen XVIII NC1 domain fusion proteins engineered to exploit matrix remodeling events","volume":"119","author":"S\u00e1nchez-Ar\u00e9valo Lobo","year":"2006","journal-title":"Int J Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.4.2.19140","article-title":"Improved stability of multivalent antibodies containing the human collagen XV trimerization domain","author":"Cuesta","year":"2012","journal-title":"MAbs"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.22698","article-title":"Generation and characterization of monospecific and bispecific hexavalent trimerbodies","volume":"4","author":"Blanco-Toribio","year":"2013","journal-title":"MAbs"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07195-w","article-title":"A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity","volume":"9","author":"Compte","year":"2018","journal-title":"Nat Commun"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.08.040","article-title":"Onco-fetal reprogramming of endothelial cells drives immunosuppressive macrophages in hepatocellular carcinoma","volume":"183","author":"Sharma","year":"2020","journal-title":"Cell"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00496-y","article-title":"Anti-angiogenic agents\u2014overcoming tumour endothelial cell anergy and improving immunotherapy outcomes","volume":"18","author":"Huinen","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-022-09863-4","article-title":"Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy","volume":"26","author":"Nowak-Sliwinska","year":"2023","journal-title":"Angiogenesis"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12624","article-title":"Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma","volume":"7","author":"Wallin","year":"2016","journal-title":"Nat Commun"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw7875","article-title":"Vascular regulation of antitumor immunity","volume":"365","author":"Munn","year":"2019","journal-title":"Science"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2025.02.017","article-title":"Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME","volume":"58","author":"Benmebarek","year":"2025","journal-title":"Immunity"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-025-01187-w","article-title":"Tumour-associated vasculature in T cell homing and immunity: opportunities for cancer therapy","volume":"25","author":"Lanitis","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20231106","article-title":"Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer","volume":"222","author":"Robles-Ote\u00edza","year":"2025","journal-title":"J Exp Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-3515","article-title":"Antiangiogenesis: vessel regression, vessel normalization, or both","volume":"82","author":"Augustin","year":"2022","journal-title":"Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1186\/s12918-019-0706-y","article-title":"How to schedule VEGF and PD-1 inhibitors in combination cancer therapy","volume":"13","author":"Lai","year":"2019","journal-title":"BMC Syst Biol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00886-y","article-title":"Antiangiogenic-immune-checkpoint inhibitor combinations: lessons from phase III clinical trials","volume":"21","author":"Kuo","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03658-y","article-title":"Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial","volume":"31","author":"Zhou","year":"2025","journal-title":"Nat Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.8595","article-title":"FDA analysis of immune checkpoint inhibitors in combination with vascular endothelial growth factor tyrosine kinase inhibitors in the second-line treatment of patients with advanced non-small cell lung cancer","volume":"42","author":"Malinou","year":"2024","journal-title":"J Clin Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-SITC2023.1194","article-title":"Mechanism of action of ivonescimab (AK112\/SMT112): a first-in-class tetravalent Fc-silent bispecific antibody with dual blockade of PD-1 and VEGF that promotes cooperative biological effects","volume":"11","author":"Zhong","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.111722","article-title":"Design of a fragment crystallizable-engineered tetravalent bispecific antibody targeting programmed cell death-1 and vascular endothelial growth factor with cooperative biological effects","volume":"28","author":"Zhong","year":"2024","journal-title":"iScience"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02722-3","article-title":"Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China","volume":"405","author":"Xiong","year":"2025","journal-title":"Lancet"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00369-1","article-title":"Ivonescimab in advanced NSCLC: is progression-free survival enough, or are overall survival data also needed","volume":"405","author":"Sankar","year":"2025","journal-title":"Lancet"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01024-y","article-title":"The evolving immuno-angiogenic paradigm in NSCLC: lessons from ivonescimab","volume":"22","author":"Herbst","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02073-w","article-title":"Ivonescimab: first approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.10613","article-title":"Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant: a randomized clinical trial","volume":"332","author":"Fang","year":"2024","journal-title":"JAMA"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2022.2044435","article-title":"A strategy for the efficient construction of anti-PD1-based bispecific antibodies with desired IgG-like properties","volume":"14","author":"Zhao","year":"2022","journal-title":"MAbs"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.8543","article-title":"A phase II trial to evaluate the safety and efficacy of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, as a monotherapy in patients with advanced NSCLC","volume":"43","author":"Wu","year":"2025","journal-title":"J Clin Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1612547","article-title":"Characterization and functional evaluation of JS207, a novel bispecific antibody against human PD-1 and VEGFA","volume":"16","author":"Lin","year":"2025","journal-title":"Front Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-39076-8","article-title":"Developing a dual VEGF\/PDL1 inhibitor based on high-affinity scFv heterodimers as an anti-cancer therapeutic strategy","volume":"13","author":"Tzuri","year":"2023","journal-title":"Sci Rep"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS8129","article-title":"A global phase III, double-blind, randomized trial of BNT327\/PM8002 plus chemotherapy compared to atezolizumab plus chemo in patients with first-line extensive-stage small cell lung cancer","volume":"43","author":"Reck","year":"2025","journal-title":"J Clin Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS8670","article-title":"A global phase 2\/3, randomized, open-label trial of BNT327\/PM8002 in combination with chemotherapy in first-line non-small cell lung cancer","volume":"43","author":"Peters","year":"2025","journal-title":"J Clin Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.2535","article-title":"Preliminary results of a phase I dose escalation study of IMM2510, a PD-L1 and VEGF bispecific fusion protein, in patients with advanced tumors","volume":"41","author":"Cheng","year":"2023","journal-title":"J Clin Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e14506","article-title":"IMM2510, an anti-PD-L1\/VEGF bispecific antibody fusion protein, in patients with advanced solid tumors: a phase I dose-escalation study","volume":"42","author":"Liu","year":"2024","journal-title":"J Clin Oncol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.778978","article-title":"A novel bispecific antibody targeting PD-L1 and VEGF with combined anti-Tumor activities","volume":"12","author":"Cui","year":"2021","journal-title":"Front Immunol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.5602","article-title":"A phase II efficacy and safety study of HB0025 (a PD-L1\/VEGF bispecific antibody) in combination with chemotherapy as first-line treatment for advanced or recurrent endometrial cancer","volume":"43","author":"Li","year":"2025","journal-title":"J Clin Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.7150\/thno.81494","article-title":"When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy","volume":"13","author":"Tapia-Galisteo","year":"2023","journal-title":"Theranostics"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-7299","article-title":"CS2009: A first-in-class trispecific antibody targeting PD-1, CTLA-4, and VEGFA with potential to be a next-generation backbone therapy with combined checkpoint inhibition and anti-angiogenesis","author":"Wang","year":"2025","journal-title":"Cancer Res"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-2726","article-title":"A novel trispecific antibody HC010 targeting PD-1\/CTLA-4\/VEGF for the potential treatment in anti-PD-1 antibody resistant NSCLC patients","volume":"84","author":"Jiang","year":"2024","journal-title":"Cancer Res"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-2712","article-title":"Development of GB268, a tri-specific antibody targeting PD-1\/CTLA-4\/VEGF, with enhanced anti-tumor efficacy and reduced toxicity in pre-clinical studies","volume":"84","author":"Du","year":"2024","journal-title":"Cancer Res"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111698","article-title":"An innovative antibody fusion protein targeting PD-L1, VEGF and TGF-beta with enhanced antitumor efficacies","volume":"130","author":"Fan","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102106","article-title":"AK112, a novel PD-1\/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (non-small cell lung cancer): an open-label, multicenter, phase II trial","volume":"62","author":"Zhao","year":"2023","journal-title":"eClinMed"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.1312","article-title":"A phase II safety and efficacy study of PM8002\/BNT327 in combination with chemotherapy in patients with EGFR-mutated non-small cell lung cancer (NSCLC)","volume":"35","author":"Wu","year":"2024","journal-title":"Ann Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1200\/OA-24-00089","article-title":"Safety and efficacy of antiangiogenesis agents in patients with squamous cell carcinoma of the lung: time to revise outdated constraints","volume":"1","author":"Pabani","year":"2024","journal-title":"JCO Oncol Adv"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1736806\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T06:47:45Z","timestamp":1769150865000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1736806\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":92,"alternative-id":["10.3389\/fimmu.2026.1736806"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1736806","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"article-number":"1736806"}}